Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414426 | 0.89 | GPR119 (0.56) | GPR119SMN1; SMN2DPP4DPP7ALDH1A1 | |
| SCHEMBL4420442 | 0.87 | GPR119 (0.77) | GPR119 | |
| SCHEMBL386190 | 0.87 | GPR119 (0.76) | GPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL4416569 | 0.86 | GPR119 (0.57) | GPR119SMN1; SMN2DPP4DPP7ALDH1A1 | |
| SCHEMBL4426169 | 0.84 | GPR119 (0.57) | GPR119SMN1; SMN2DPP4DPP7ALDH1A1 | |
| SCHEMBL4415920 | 0.84 | GPR119 (0.54) | GPR119 | |
| SCHEMBL609466 | 0.83 | GPR119 (0.55) | GPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL612271 | 0.82 | GPR119 (0.56) | GPR119ALDH1A1 | |
| SCHEMBL609296 | 0.81 | GPR119 (0.55) | GPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL610359 | 0.81 | GPR119 (0.54) | GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885SMN1; SMN2 2663/4885DPP4 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.